Guggenheim Downgrades 10x Genomics to Neutral
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Subbu Nambi has downgraded 10x Genomics (NASDAQ:TXG) from Buy to Neutral.

June 25, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Guggenheim analyst Subbu Nambi has downgraded 10x Genomics from Buy to Neutral, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Neutral by a reputable analyst suggests a less favorable view on the stock's short-term performance, likely leading to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100